Displaying drugs 76 - 100 of 2778 in total
| Name | Weight | Structure | Description | Categories |
|---|---|---|---|---|
| Padeliporfin | 840.26 C37H43N5O9PdS |  | A vascular-acting photosensitizer used to treat low-risk prostate cancer in adults. | Sensitizers Used in Photodynamic/radiation Therapy |
| Sotorasib | 560.606 C30H30F2N6O3 |  | An experimental KRAS inhibitor being investigated for the treatment of KRAS G12C mutant non small cell lung cancer, colorectal cancer, and appendix cancer. | Immune Checkpoint Inhibitors |
| Adagrasib | 604.13 C32H35ClFN7O2 |  | A KRAS inhibitor indicated for the treatment of locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer in patients who have received at least one prior systemic therapy. | Antineoplastic Agents |
| Prednisolone acetate | 402.4807 C23H30O6 |  | A glucocorticoid used to treat a wide variety of endocrine, inflammatory, and immune conditions as well as for palliation of neoplastic conditions. | Anti-Inflammatory Agents / Prodrugs |
| Magnesium malate | 156.376 C4H4MgO5 |  | Not Annotated | Not Annotated |
| Ferric chloride | 162.204 Cl3Fe |  | Not Annotated | Caustics / Noxae |
| Colchiceine | 385.416 C21H23NO6 |  | Colchiceine is one of several metabolites of the anti-gout medication colchicine. | Alkaloids / Colchicine Derivatives / Tubulin Inhibiting Agent |
| Edotreotide gallium Ga-68 | 1486.55 C65H89GaN14O18S2 |  | A radioactive diagnostic agent used in PET scans for somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients. | Gallium Radioisotopes |
| Zuranolone | 409.574 C25H35N3O2 |  | A neuroactive steroid drug used to treat postpartum depression | Central Nervous System Agents / Psychotropic Drugs |
| Resorcinol monoacetate | 152.149 C8H8O3 |  | Not Annotated | Benzene Derivatives / Phenols |
| Zirconium chloride hydroxide | 143.68 ClHOZr |  | Not Annotated | Not Annotated |
| Alloin | 418.398 C21H22O9 |  | Not Annotated | Laxatives |
| Cinoxate | 250.294 C14H18O4 |  | Not Annotated | Sunscreen Agents |
| Benzhydrocodone | 403.478 C25H25NO4 |  | Benzyhydrocodone is indicated, in combination with acetaminophen, for the short-term management of acute pain requiring opioid therapy. | Opioids |
| Belzutifan | 383.34 C17H12F3NO4S |  | An inhibitor of hypoxia-inducible factor 2α used as an antineoplastic in the treatment of certain cancers associated with von Hippel-Lindau (VHL) disease. | Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Hypoxia-inducible Factor Inhibitor / MATE 2 Inhibitors / MATE inhibitors / OATP1B1/SLCO1B1 Substrates / OATP1B3 substrates / P-glycoprotein substrates / UGT2B17 substrates |
| Vericiguat | 426.388 C19H16F2N8O2 |  | A soluble guanylate cyclase stimulator used to reduce heart failure-related hospitalization and cardiovascular death in patients with chronic systolic heart failure. | Soluble Guanylate Cyclase Stimulator |
| Elexacaftor | 597.66 C26H34F3N7O4S |  | A small molecule CFTR corrector used in combination with tezacaftor and ivacaftor for the treatment of cystic fibrosis patients with one F508del-CFTR mutation. | Cystic Fibrosis Transmembrane Conductance Regulator Correctors / Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP2B6 Inhibitors / Cytochrome P-450 CYP2B6 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP2D6 Inhibitors / Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A4 Substrates (strength unknown) / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Membrane Transport Modulators / OATP1B1/SLCO1B1 Inhibitors / OATP1B3 inhibitors / P-glycoprotein inhibitors / P-glycoprotein substrates |
| Trilaciclib | 446.559 C24H30N8O |  | A CDK4 and CDK6 inhibitor to reduce the risk of chemotherapy induced myelosuppression. | Detoxifying Agents for Antineoplastic Treatment |
| Pafolacianine | 1326.49 C61H67N9O17S4 |  | An optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. | Molecular Probes / Optical Imaging Agent |
| Danicopan | 580.418 C26H23BrFN7O3 |  | A small molecule complement factor D inhibitor used to treat extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria. | Amines / Amino Acids / Amino Acids, Cyclic / Amino Acids, Peptides, and Proteins / BCRP/ABCG2 Inhibitors / Complement Inactivating Agents / Heterocyclic Compounds, Fused-Ring / Imino Acids / P-glycoprotein inhibitors / Pyrazoles / Pyridines |
| Tilmanocept | Not Annotated |  | Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis... | Not Annotated |
| Ubrogepant | 549.554 C29H26F3N5O3 |  | An oral CGRP antagonist used in the acute treatment of migraine with or without aura. | Calcitonin Gene-Related Peptide (CGRP) Antagonists |
| Risdiplam | 401.474 C22H23N7O |  | An oral mRNA splicing modifier used in the treatment of spinal muscular atrophy (SMA). | BCRP/ABCG2 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / MATE 1 Inhibitors / MATE 2 Inhibitors / MATE inhibitors / Musculo-Skeletal System / Other Miscellaneous Therapeutic Agents / P-glycoprotein substrates / Peripheral Nervous System Agents / Survival Motor Neuron-2-directed RNA Interaction / Survival of Motor Neuron 2 Splicing Modifier |
| Avapritinib | 498.57 C26H27FN10 |  | A selective tyrosine kinase inhibitor being investigated for the treatment of multidrug resistant gastrointestinal tumors. | Kinase Inhibitor |
| Futibatinib | 418.457 C22H22N6O3 |  | A kinase inhibitor used to treat intrahepatic cholangiocarcinoma in previously treated adults. | Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors |
Displaying drugs 76 - 100 of 2778 in total